The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Ted has told me about some of the most terrifying cases are the exact opposite these guys that show up with a low PSA with a very low PSA a PSA of 1.9 those are worse and for sure uh rampant metastatic disease right right right and that's the thing you get some of these really poorly differentiated cancer that no longer resemble their prostate progenitor cells and they just they're very hard to monitor and a lot of them even don't even show up on a PSMA PET scan
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.